Latest Insider Transactions at Cin Cor Pharma, Inc. (CINC)
This section provides a real-time view of insider transactions for Cin Cor Pharma, Inc. (CINC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CinCor Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CinCor Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2023
|
5 Am Partners Vi, LLC > 10% Shareholder |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
4,937,646
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
6,073,949
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,608
-100.0%
|
-
|
|
Feb 24
2023
|
James Healy Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,803
-33.33%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
100
-100.0%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,000
-100.0%
|
-
|
|
Feb 24
2023
|
Mason Freeman Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
2,494
-5.87%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
1,500
-100.0%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 24
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
140,149
-90.33%
|
-
|
|
Feb 24
2023
|
Michael Wayne Kalb EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
202,437
-100.0%
|
-
|
|
Feb 24
2023
|
Marc De Garidel Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
200,000
-100.0%
|
-
|
|
Feb 24
2023
|
Marc De Garidel Chief Executive Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
12,500
-5.88%
|
-
|
|
Jan 26
2023
|
Michael Wayne Kalb EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
177,000
+46.65%
|
-
|
|
Jan 26
2023
|
Catherine Pearce Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+8.82%
|
-
|
|
Jan 26
2023
|
Marc De Garidel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+48.48%
|
-
|
|
Jan 26
2023
|
Mason Freeman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+48.48%
|
-
|
|
Jan 11
2023
|
Catherine Pearce Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,997
-2.77%
|
$111,916
$28.75 P/Share
|
|
Jan 11
2023
|
Catherine Pearce Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,235
+8.41%
|
-
|
|
Nov 28
2022
|
James Healy Director |
SELL
Open market or private sale
|
Indirect |
6,000
-100.0%
|
$84,000
$14.32 P/Share
|
|
Nov 04
2022
|
Michael Wayne Kalb EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,437
+50.0%
|
-
|
|
Aug 15
2022
|
Sofinnova Partners Sas > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
133,333
+3.06%
|
$3,999,990
$30.0 P/Share
|
|
Aug 15
2022
|
5 Am Partners Vi, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+26.39%
|
$18,000,000
$30.0 P/Share
|
|
Aug 11
2022
|
Sofinnova Venture Partners X, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+7.61%
|
$15,000,000
$30.0 P/Share
|
|
Aug 11
2022
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
506,000
+28.8%
|
$15,180,000
$30.0 P/Share
|
|
Aug 11
2022
|
General Atlantic LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
83,000
+1.93%
|
$2,490,000
$30.0 P/Share
|
|
Aug 11
2022
|
General Atlantic Genpar (Bermuda), L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
83,000
+1.93%
|
$2,490,000
$30.0 P/Share
|
|
Aug 05
2022
|
James Healy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,411
+50.0%
|
$382,343
$13.6 P/Share
|
|
Jun 10
2022
|
Mason Freeman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6
-0.24%
|
$90
$15.21 P/Share
|
|
Jan 11
2022
|
Mary Theresa Coelho EVP CFO & Chief BD Officer |
BUY
Open market or private purchase
|
Indirect |
100
+50.0%
|
$1,600
$16.0 P/Share
|
|
Jan 11
2022
|
Marc De Garidel Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
12,500
+50.0%
|
$200,000
$16.0 P/Share
|
|
Jan 11
2022
|
Mason Freeman Chief Medical Officer |
BUY
Open market or private purchase
|
Indirect |
100
+50.0%
|
$1,600
$16.0 P/Share
|
|
Jan 11
2022
|
Mason Freeman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$40,000
$16.0 P/Share
|
|
Jan 11
2022
|
Catherine Pearce Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
1,500
+50.0%
|
$24,000
$16.0 P/Share
|
|
Jan 11
2022
|
Catherine Pearce Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
750
+0.57%
|
$12,000
$16.0 P/Share
|
|
Jan 11
2022
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
325,000
+5.51%
|
$5,200,000
$16.0 P/Share
|
|
Jan 11
2022
|
James Healy Director |
BUY
Conversion of derivative security
|
Indirect |
5,248,949
+50.0%
|
-
|
|
Jan 11
2022
|
Sofinnova Partners Sas > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
220,000
+5.11%
|
$3,520,000
$16.0 P/Share
|
|
Jan 11
2022
|
Sofinnova Partners Sas > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,867,646
+50.0%
|
-
|
|
Jan 11
2022
|
Sofinnova Venture Partners X, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
325,000
+5.51%
|
$5,200,000
$16.0 P/Share
|
|
Jan 11
2022
|
Sofinnova Venture Partners X, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
5,248,949
+50.0%
|
-
|
|
Jan 11
2022
|
Cin Rx Pharma, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,222,530
+25.19%
|
-
|
|
Jan 11
2022
|
5 Am Partners Vi, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
470,000
+21.29%
|
$7,520,000
$16.0 P/Share
|
|
Jan 11
2022
|
5 Am Partners Vi, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,867,646
+50.0%
|
-
|
|
Jan 11
2022
|
General Atlantic Genpar (Bermuda), L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,700,000
+29.18%
|
$27,200,000
$16.0 P/Share
|
|
Jan 11
2022
|
General Atlantic Genpar (Bermuda), L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,426,470
+50.0%
|
-
|
|
Jan 11
2022
|
General Atlantic LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,700,000
+29.18%
|
$27,200,000
$16.0 P/Share
|
|
Jan 11
2022
|
General Atlantic LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,426,470
+50.0%
|
-
|